This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutStudy Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 36-month overall efficacy1L 36-month CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementDosingTherapy management

The information on this website is based on data from adult patients with ALK-positive advanced NSCLC (anaplastic lymphoma kinase positive advanced non small cell lung cancer) treated with LORVIQUA(lorlatinib), produced in line with the LORVIQUA (lorlatinib) Summary of Product Characteristics.
LORVIQUA (lorlatinib) Prescribing Information click here.
LORVIQUA is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. Adverse event reporting information can also be found at the bottom of the page.

Efficacy of LORVIQUA as a First Line Agent in ALK+ Advanced NSCLCLORVIQUA significantly improved progression-free survival vs crizotinib1,2 Progression-free survival by BICR (ITT population, N=296)1,2

Data cutoff: 20 March 2020.2

  • Patients receiving LORVIQUA experienced longer PFS vs crizotinib, irrespective of baseline patient and disease characteristics1,2
  • At data cutoff, OS data were not mature2
Progression-free survival (BICR assessed): subgroup analysis4

Data cutoff: 20 March 2020.2
Adapted from: Supplement to Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators.
First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):
2018-2029. 

This graph depicts prespecified exploratory subgroup analyses from the CROWN trial. Small patient numbers can be a limitation of subgroup analyses. These results are presented for descriptive purposes and should not be interpreted as a demonstration of efficacy in any particular subgroup.

Improved tumour response with LORVIQUA vs crizotinib1,2 ORR (ITT population, N=296)a

aDefined as confirmed complete response or partial response as assessed by BICR.1,2 
Data cutoff: 20 March 2020.2

  • Median DoR: Not estimable (95% Cl, NE-NE) with LORVIQUA vs 11 months (95% Cl, 9-13) with crizotinib1,2
  • Response duration ≥12 months: 70% with LORVIQUA vs 27% with crizotinib3
BICR=blinded independent central review; CNS=central nervous system; DoR=duration of response; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; ITT=intention to treat; NE=not estimable; ORR=objective response rate; OS=overall survival; PFS=progression-free survival.ReferencesReferences:

1. Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics. 

2. Solomon, Bauer at al; Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 2023;11: 354–663. Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.
4. Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. [supplementary appendix]N Engl J Med. 2020;383(21):2018-2029.
Efficacy
LORVIQUA safety profile
Review the safety
PP-LOR-IRL-0068 February 2024 Legal Category S1A Further Information Available on Request

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024